1

CURRICULUM VITAE

DAVID S.H. BELL, M.B., FACP,FRCPUK(Ed), FRCPS(Canada),FACE

Business Address:

1900 Crestwood Blvd

Suite 201

Irondale, AL 35210

Clinic Telephone: (205) 957.0034

Clinic Fax: (205) 957.0036

E-mail: dshbell@yahoo.com

Birthplace: Armagh N. Ireland

Citizenship: USA

Married Status: Married

Children: Three

EDUCATION: Belfast Royal Academy, 1955-1962

Queens University, Belfast Dental School, 1962-1965

Queens University School of Medicine, 1965-1970

Graduated MB, B. Ch., B.A.O., 1970

POSTGRADUATE TRAINING

Intern in Medicine, Royal Victoria Hospital, Belfast, N. Ireland, 1970-1971

Resident in Internal Medicine, Royal Victoria Hospital, Belfast, N. Ireland, 1971-1973

Resident in Internal Medicine, Royal University Hospital, Saskatoon, Saskatchewan,

Canada, 1973-74

Fellow in Endocrinology, Royal University Hospital, Saskatoon, Saskatchewan, Canada,

1974-1975

Fellow in Endocrinology, Greater Baltimore Medical Center, Towson Md, USA, 1975-1976

FACULTY POSITIONS HELD

Tutor in Medicine, Queens University, Belfast, 1971-1972

Tutor in Pharmacology and Therapeutics, Queens University, Belfast, 1972-1973

Teaching Fellow, University of Saskatchewan, Saskatoon, 1974-1975

Assistant Professor of Medicine, Temple University School of Medicine, 1978-1980

Clinical Assistant Professor of Medicine, Pennsylvania State University College of Medicine

1978-1980

Associate Professor of Medicine, University of Alabama at Birmingham, 1980-1987

Professor of Medicine, University of Alabama at Birmingham School of Medicine 1987-2005

Adjunct Clinical Professor of Medicine, University of Alabama Medical School,

Birmingham, AL 2005-present

2

David S.H. Bell

HONORS

2nd in Class Final Part 1 – 1969

Top 20 in Class Final Part 2 - 1970

Fellow, Royal College of Physicians and Surgeons of Canada, 1976

Fellow, American College of Physicians – 1983

Fellow, Royal College of Physicians of Edinburgh – 1986

Birmingham’s Best Doctors -2008-2015

Named in the “The Best Doctors in America”, 2001-2015

Named one of America’s Top Doctors, 2001-2015

Top Doctors for men in Men’s Health, 2007

Top Doctors for women in Women’s Health, 2008

Received the 2001 Distinguished Clinician award from the American College of

Endocrinology for outstanding contribution to the field of Endocrinology as a master

educator and clinician

Received the 2002 Southern Medical Association’s Seale Harris Award for superior

contributions to the art and science of diabetes and endocrinology

Top 30% Reviewers for Annals of Internal Medicine -2008

USA Today Most Influential Doctors in Diabetes and Lipids - 2009

America's Most Compassionate Doctors - 2012

BOARD CERTIFICATION

Advanced Achievement in Internal Medicine, 1987

American Board of Internal Medicine (Endocrinology Subspecialty Certification), 1981

American Board of Internal Medicine, 1976

Royal College of Physicians and Surgeons of Canada, 1975

Royal College of Physicians of the United Kingdom, 1973

Professional Organizations

American College of Physicians, member 1977-1982, fellow 1983-present

Royal College of Physicians of Edinburgh, member 1973-1986, fellow 1986-present

Royal College of Physicians and Surgeons of Canada, 1976-present

Endocrine Society, 1990-present

American College of Endocrinology, 1994-Present

American Association of Clinical Endocrinologists, 1991-Present

Charter Member 1991

Board of Directors, 2014-Present

American Medical Association, 1978-Present

American Diabetes Association, 1978-Present

3

David S.H. Bell

EDITORIAL BOARDS

Endocrine Practice 2000-2005

Treatments in Endocrinology 2001-2005

Diabetes Obesity and Metabolism 2002-present

Endocrine Today 2006-present

Diabetes Therapy 2015-present

ADMINISTRATIVE APPOINTMENTS

District Coroner in Province of Ontario, 1976-1978

Conemaugh Valley Memorial Hospital, Johnstown PA

Director, Internal Medicine Residency Program, 1978-1980

Director, Physicians Continuing Education, 1978-1980

University of Alabama at Birmingham

Director of Clinical Services, Diabetes Research and Education Hospital, 1980-1992

Director Adolescent Diabetes Unit 1982-1985

Clinical Director, Endocrinology Clinic, The Kirklin Clinic, 1992-1997

Director, Clinical Research, Division of Endocrinology, 1998-2003

HOSPITAL APPOINTMENTS

Georgetown Memorial Hospital, Georgetown, Ontario, Canada 1976-1978

Conemaugh Valley Memorial Hospital, Johnstown, PA, 1978-1980

University of Alabama at Birmingham Hospital, 1980-2005

Eye Foundation Hospital, Birmingham, AL, 1981-1990

STATE LICENSURE:

General Medical Council of the United Kingdom 1970-1973

Saskatchewan, 1973-1975

Maryland, 1975-1976

Ontario, 1976-1981

Pennsylvania, 1978-1981

Alabama, 1980 – present (License #09301)

4

David S.H. Bell

PUBLICATIONS

1. Bell DSH, Moyer JH: Vasodilator drugs for peripheral vascular disturbances. In:

Modell W (ed): Drugs of Choice 1980-1981. C.V. Mosby, St. Louis (1980)441-449.

2. Clements RS Jr, Bell DSH: Diagnostic pathogenetic and therapeutic aspects of

diabetic neuropathy. In Special Topics in Endocrinology and Metabolism, Cohen

M.P. and Foa P.P. (eds): A.R. Liss, Inc., New York, (1981)1-143.

3. Pittman W, Acton R, Barger B, Bell DSH, Go R, Murphy C, roseman J: HLA-A, -B,

and –DR Associations in Type 1 Diabetes Mellitus with Onset After Age Forty.

Diabetes (1982)31:122-125.

4. Clements RS Jr, Bell DSH: Diabetic Neuropathy. Peripheral and autonomic

syndromes. Postgraduate Medicine (1982)71(6) 50-67.

5. Clements RS Jr, Bell DSH: Candidate mechanism for the pathogenesis of diabetic

neuropathy. In: Diabetes and its Late Complications. Cudworth AG, Andreani D,

Bodansky HJ, Squadrito G (eds): John Libbey, London (1982)119-126.

6. Fairclough PK, Clements RS Jr., Filer DV, Bell DSH: An evaluation of patient

performance of and their satisfaction with various rapid blood glucose measurement

systems. Diabetes Care (1983) 6:45-49.

7. Bell DSH, Clements RS Jr., : Reversal of the carpal tunnel syndrome after change of

insulin injection sites. Diabetes Care (1983)6:45-46.

8. Bell DSH, Christian SR, Clements RS Jr.: Acuphobia in a long-standing insulin-

dependent diabetic cured by hypnosis. Diabetes Care (1983) 6:622.

9. Bell DSH: Amitriptyline versus placebo in post-herpetic neuralgia. Neurology (1983)

33:1530.

10. Bell DSH: MIST: Medical Information via Telephone. Alabama Journal of Medical

Sciences (1985) 22:311-314.

11. Bell DSH: Immunotherapy of Diabetes. Dial Access of the Southern Medical

Association, 1984.

12. Bell DSH, Acton R: Immunotherapy of insulin-dependent diabetes. Alabama

Journal of Medical Sciences (1985) 22:311-314.

13. Bell DSH: Exercise guidelines for the diabetic. Sports and Medcina (1985)5:31-33.

5

David S.H. Bell

14. Hodge TW, Barger BO, Littrell MN, Bell DSH, Go RCP, Acton RT: DR-B restriction

fragment length polymorphisms associated with insulin-dependent diabetes mellitus.

Biochemical Society Transaction (1985)79(5A)1-7.

15. Clements RS Jr, Bell DSH: Diabetic complications – prevalence, detection, current

treatment and prognosis. Amer J. Medicine (1985) 79(5A) 1-7.

16. Clements RS Jr, Bell DSH: Diabetic Neuropathy Part 1. Diabetic Complications

(1985) 1:1-3.

17. Clements RS Jr, Bell DSH: Diabetic Neuropathy Part II. Diabetic Complications

(1985) 2:1-4.

18. Bell DSH, Clements RS Jr: Selection of patients for insulin pump therapy. Practical

Cardiology (1986) 12:57-71.

19. Clements RS Jr, Bell DSH: Intensive insulin therapy – rationale and methods.

Research Update (1986) 1:1-8.

20. Bell DSH, Clements RS Jr.: Rapid insulin initiation in NIDDM: Effect on B-cell

function and insulin resistance. Proceedings of 1st International Novo Symposium on

Non-Insulin-Dependent Diabetes. Editor, R. Tattersal: (1987)61-66.

21. Clements RS Jr, Bell DSH, Benbarka A, Capper SA: Rapid insulin initiation in non-

insulin dependent diabetes mellitus. Amer J. Medicine (1987)82:415-420.

22. Hughes TA, Clements RS, Fairclough PK, Bell DSH, Segrest JP: Effect of insulin

therapy on lipoproteins in NIDDM. Atherosclerosis (1987) 67:105-114.

23. Bell DSH, Acton RT, Barger BO, Vanichanan C, Clements RS Jr.: The futility of

predicting the onset of insulin-dependent diabetes. Diabetes Care (1987) 10:788-789.

24. Bell DSH, Clements RSJr.: Diabetes and the digestive system. Diabetes Forecast

(1987)12:43-46.

25. Bartholomew G, Radu B, Bell DSH: Oral candidiasis in insulin-dependent diabetes.

Diabetes Care (1987) 10:604-606.

26. Bell DSH, Ackerson C, Cutter G, Clements RSJr.: Factors associated with

discontinuation of continuous subcutaneous insulin. American Journal of Medical

Sciences (1988) 295:23-28.

6

David S.H. Bell

27. Bell DS, Clements RS, Cutter GR, Whitley RJ. Condylomata acuminata in IDDM.

Diabetes Care (1988) 11(3):295-6.

28. Bell DSH, Clements RS Jr.: Prediction and Immunosuppression of Type 1 Diabetes.

Reply, Diabetes Care (1988) 11:511.

29. Bell DS. Failure to recognize that hypoglycemia may be a problem associated with

insulin manufactured by the recombinant DNA method. Clin Ther 1989 11(5)707-

708.

30. Bell DSH: Hypertension in the person with diabetes. American Journal of Medical

Sciences. (1989) 297:228-232.

31. Lauritano AA, Clements RS, Bell DSH: Insulin antibodies in non-insulin-dependent

diabetes mellitus: Effect of treatment with semi-synthetic human insulin. Clinical

Therapeutics (1989) 2:268-277.

32. Bell DSH: Improved Treatment of NIDDM: Fixed-Ratio Insulin Regimens in:

Making Life Better for the Insulin-Using Patient. A Special Report. Postgraduate

Medicine (1989)10:27-34.

33. Bell DSH: Pathogenesis and Prevention of Insulin-Dependent Diabetes. Southern

Medical Association, Dial Access Program, 1989.

34. Bell DSH: Pentoxifylline in the Treatment of Microcirculatory Disorders. A Review

of the Literature. Ed. Bell DSH. Excerpta Medica Princeton, USA (1989)1-4.

35. Bell DSH: Topics in Clinical Research III. The importance of randomized, double-

blind procedures in clinical trials. Clinical Therapeutics (1989)11(5) 652-658.

36. Clements RS Jr., Bell DSH. Increased responsiveness to exogenous insulin

administration in the hypeglycemic obese person with type II diabetes. Clinical

Therapeutics (1989) II(5) 652-658.

37. Bell DSH. The importance of double-blinding. Clinical Therapeutics (1989)11(5)707-

708.

38. Bell DSH, Cutter GR, and Lauritano AA. Efficacy of a premixed semisynthetic

insulin regimen. Clinical Therapeutics (1989)11:795-801.

7

David S.H. Bell

39. Acton RT, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Barger BO, Bell DSH,

Goldenberg RL, Winkler CL, Tucker JM, Hauth JC, and Huddleston JF.

Immunogenetic Predictors of Gestational Diabetes in American Blacks in

Immunology of Normal and Diabetic Pregnancy, edited by D. Andreani, GD

Bompiani, U Di Mario, S.P. Faulk and A. Galluzzo. John Wiley & Sons LTD (1990)

Chapter 12, Pages 207-220.

40. Bell DSH. Sulfonylurea failure in non-insulin-dependent diabetes mellitus. American

Journal of Medicine (1990)89:446-447.

41. Bell DSH, Clements RS Jr., Perentesis GP. Hypoglycemia in children with insulin-

dependent diabetes mellitus. J. Pediatr (1990) 117:340.

42. Bell DSH, Barger BO, Go RCP, Goldenberg RL, Perkins LL, Vanichanan CJ,

Roseman J, Acton RT. Risk factors for gestational diabetes in the black population.

Diabetes Care (1990) 13(11):1196-1201.

43. Bell DSH. Hazards of Inaccurate Readings Obtained by Self-Monitoring of Blood

Glucose. Diabetes Care (1990) 13:1131-1132.

44. Williams BT, Ketchum CH, Robinson A, and Bell DSH. Screening for slight

albuminuria: A comparison of selected commercially available methods. Southern

Medical Journal (1990) 83:1447-1449.

45. Bell DSH. Diabetic nephropathy: Changing concepts of pathogenesis and treatment.

The American Journal of the Medical Sciences (1991) 301:195-200.

46. Tucker JM, Winkler CL, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP,

Bell DSH, Perkins LL, Vanichanan CJ, and Roseman JM. Autoantibodies in black

women with class A1 or class GB diabetes mellitus. American Journal of

Perinatology (1991) 8:103-105.

47. Winkler CL, Tucker JM, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP,

Bell DSH, Perkins LL, Vanichanan CJ, and Roseman JM. Histocompatability

antigen subtypes in black women with class A1 or Class GB diabetes mellitus.

American Journal of Perinatology (1991) 8:106-109.

48. Bell DSH. Lower limb problems in diabetic patients. What are the causes? What are

the remedies? Postgraduate Medicine (1991) 89:237-244.

49. Bell DSH, Bode B, Clements RS Jr., Herron J, Hollander P, Kumar D, Perentesis GP,

Sosenko J. Premixed vs. Self-mixed insulin in the treatment of type II diabetes

mellitus: A randomized trial. Today’s Therapeutic Trends. The Journal of New

Developments in Clinical Medicine (1991) 9:63-73.

8

David S.H. Bell

50. Bell DSH, Clements RS, Perentesis G, Roddam R, and Wagenknecht L. Dosage

accuracy of self-mixed vs. premixed insulin. Archives of Internal Medicine (1991)

151:2265-2269.

51. Bell DSH, Wagenknecht LE. Effect of gemfibrozil on intermediate density

lipoproteins in NIDDM patients. Diabetes Care (1992) 15:146-147.

52. Aikens JE, Wallander JL, Bell DSH, and Cole JA. Daily stress variability, learned

resourcefulness, regimen adherence, and metabolic control in type 1 diabetes mellitus:

Evaluation of a path model. Journal of Consulting and Clinical Psychology (1992)

60:113-118.

53. Roseman JM, Go RCP, Perkins L, Barger B, Bell DSH, Goldenberg RL, DuBard MB,

Huddleston JF, Sedlacek CM, and Acton RT. Gestational diabetes mellitus among

African-American women. Diabetes/Metabolism Reviews (1991) 93-104.

54. Bell DSH, Ketchum CH, Robinson CS, Wagenknecht LE, Williams BT.

Microalbuminuria associated with diabetic neuropathy. Diabetes Care (1992) 15:528-

531.

55. Bell DSH. Hypoglycemia induced by Enalapril in patient with insulin resistance and

NIDDM. Diabetes Care (1992)15:934-935.

56. Bell DSH. Milk allergy masquerading as insulin allergy. Diabetes Care (1992)

15:934-935.

57. Bell DSH. Diabetic nephropathy associated with insulin-dependent diabetes. Internal

Medicine (2) (1992) Medifacts, Ottawa Canada.

58. Bell DSH. Exercise for patients with diabetes – benefits, risks, and precautions.

Postgraduate Medicine (1992) 92:183-198.

59. Bell DSH, Cutter GR, Hayne VB, and Lloyd LK. Factors predicting efficacy of

phentolamine-papaverine intracorporeal injection for treatment of erectile

dysfunction in the diabetic male. Urology (1992) 40:36-40.

60. Bell DSH. Diabetic foot problems. Family Practice (1992) 2(6). Medifacts Ottawa,

Canada.

61. Bell DSH. Diabetes and hypertension – prevalence and therapy. Cardiology (1992)

(6). Medifacts Ottawa, Canada.

9

David S.H. Bell

62. Bell DSH, Cutter G, Clements RS, Jr. The feasibility of long-term treatment of

diabetes with continuous subcutaneous insulin infusion. Diab. Nutr. Metab. (1993)

6:57-60.

63. Bell DSH. Insulin resistance: an often unrecognized problem accompanying chronic

medical disorders. Postgraduate Medicine (1993) (937) 99-107.

64. Acton RT, Bell DSH, Go RC, Roseman J. Association of HLA phenotypes with

hypertension in African Americans and Caucasoid Americans with type II diabetes, a

population at risk for renal disease. Transplant Proc (1993) 25:2400-2403.

65. Bell DSH. The graveyard shift. Diabetes Forecase (1994) 47:47-49.

66. Chiu KC, Go RCP, Aoki M, Riggs AC, Tanizawa Y, Acton RT, Bell DSH, Goldenerg

RL, Roseman JM, Permutt MA. Glucokinase gene in gestational diabetes mellitus:

population association study and molecular scanning. Diabetologia (1994) 37:104-

110.

67. Bell DSH. Stroke in the diabetic patient. Diabetes Care (1994) 17:217-219.

68. Bell DSH, Cutter G. Characteristics of severe hypoglycemia in the patient with

insulin-dependent diabetes. Southern Medical Journal (1994) 87(6)616-620.

69. Bell DSH. Insulin pump therapy for the 90’s. The Endocrinologist (1994) (4)270-278.

70. Acton RT, Roseman JM, Bell DSH, Goldenberg RL, Tseng ML, Vanichanan LA,

Harman LA, Go RCP. Genes within the major histocompatibility complex predict

NIDDM in African American Women in Alabama. Diabetes Care (1994) 17:1491-

1494.

71. Bell DSH. Stopping those swinging sugars. Diabetes Forecast (1994)47:36-40.

72. Tanizawa Y, Riggs AC, Chiu KC, Janssen RC, Bell DSH, Go RPC, Roseman JM,

Acton RT, Permutt MA. Variability of the pancreatic islet beta cell/liver (GLUT 2)

glucose transporter gene in NIDDM patients. Diabetologia (1994) 420-427.

73. Aikens JE, Wallander JL, Bell DS, McNorton A. A nomothetic-idiographic study of

daily psychological stress and blood glucose in women with type 1 diabetes mellitus. J

Behav Med (1994) 17(6)535-48.

74. Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary

artery disease? Diabetes Care (1995) 18:708-714.

10

David S.H. Bell

75. Bell DSH. To hurt or not to hurt. Diabetes Forecast (1995) 48(6)30-33.

76. Bell DSH. How to manage stroke in patients with diabetes: Strategies for diagnosis,

treatment and prevention. The Journal of Critical Illness (1995) 10(5)317-328.

77. Bell DSH. Myocardial infarction and stroke in diabetic patients. Diabetes

Metabolism. (1995) 40:1-4.

78. Bell DSH. Lack of long-term diabetic complications in spite of poor glycemic control

in twins with pure gonadal dysgenesis. Diabetes Care (1995) 18:1286-1287.

79. McCarren M, Bell DSH. Prepare to pump. Diabetes Forecast (1995) September 33-

39.

80. Bell DSH, Grizzle WE, Dunlap NE. Nesidoblastosis causing reversal of insulin-

dependent diabetes and development of hyperinsulinemic hypoglycemia. Diabetes

Care (1995) 18:1379-1380.

81. Bell DSH. Night shift work and the diabetic patient. The Endocrinologist (1995)

5:344-346.

82. Bell DSH. Non-diabetic neuropathy in a patient with diabetes. Endocrine Practice

(1995) 1(6) 393-394.

83. Bell DSH. A comparison of lovastatin, an HMG-COA reductase inhibitor, with

gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic

dyslipidemia. Clinical Therapeutics (1995) 17:901-910.

84. Bell DSH, Yumuk VD. Low incidence of false-positive exercise thallium 201

scintigraphy in a diabetic population. Diabetes Care (1995) 19(2)185.

85. Bell DSH. Profiles of stroke in the diabetic patient. Advances in Cardiovascular

Medicine (1996) 3:1-8.

86. Bell DSH. Alcohol and the NIDDM patient. Diabetes Care (1996) 19:509-513.

87. Bell DSH. Myocardial infarction in the diabetic patient. The Endocrinologist (1996)

6:196-206.

88. Bell DSH, Acton RT. Increased prevalence of mitral valve prolapse in IDDM.

Diabetes Care (1996) 19:672.

11

David S.H. Bell

89. Bell DSH. Diabetes mellitus and coronary artery disease. Coronary Artery Disease

(1996) 7(10)715-722.

90. Decrease in mortality from diabetic nephropathy in Pima Indians. Diabetes Care

(1996) 19:779.

91. Bell DSH, Mayo MS. Outcome of metformin-facilitated reinitiation of oral diabetic

therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus.

Endocrine Practice (1997) 3:73-76.

92. Bell DSH, Alele J. Diabetic ketoacidosis. Postgraduate Medicine (1997) 101:193-203.

93. Bell DSH. New modalities for the treatment of NIDDM: Acarbose and metformin.

Consultant Pharmacist 12(suppl A)7-11,1997.

94. Bell DSH. Management of Diabetes: Medications. In Diabetes Medical Nutrition

Therapy. Holler HJ, Pastors JG, Eds. The American Dietetic Association (1997) 35-

42.

95. Bell DSH. Management of Diabetes: Complications. In Diabetes Medical Nutrition

Therapy. Holler JH, Pastors JG, Eds. The American Dietetic Association (1997) 75-

82.

96. Bell DSH. Diabetes mellitus and coronary artery disease. Journal of Cardiovascular

Risk (1997) 4(2)83-90.

97. Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-

dependent diabetes mellitus treated with sulfonylureas or insulin. Endocrine Practice

(1997) 3:281-283.

98. Bell DSH. Converting patients with type 2 diabetes from insulin-requiring to non-

insulin-requiring. Clinical Diabetes (1997) 15(5) 205-207.

99. Bell DSH. Reinitiation of oral hypoglycemic therapy – the Alabama Experience in

Proceedings of the Combined Insulin/Oral Agent Therapy: Satellite Symposium to

the 1997 Postgraduate Meeting – Baylor College of Medicine, Houston, TX (1997) 29-

34.

100. Bell DSH. Effective Analgesia. BMJ (1997) 315:1411.

12

David S.H. Bell

101. Acton RT, Bell DSH, Collins JN, Go RCP, Harrison R, McDonald R, Rivers C,

Roseman JM, Taylor HA, and Vanichanan C. Genes within and flanking the major

histocompatibility region are risk factors for diabetes, insulin resistance,

hypertension, and microalbuminuria in African-American women. Transplantation

Proceedings (1997) 29:3710-3712.

102. Bell DSH. University Group Diabetes Program – “Déjà vu all over again?"

Endocrine Practice (1998) 4:6465.

103. Bell DSH, Mayo MS. Improved glycemic control with use of oral hypoglycemia

therapy with or without insulin. Endocrine Practice (1998) 4(2)82-85.

104. Bell DSH. Managing type 2 diabetes patients who require insulin. In Successful

Strategies for the Control of Type 2 Diabetes. Eds. Garber AJ, Bell DSH, Reasner C,

James W. Postgraduate Institute for Medicine. Littleton, CO 1998 10-13.

105. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus.

Endocrine Practice (1998) 4:146-147.

106. Bell DSH, Kudlow J, Tidwell M. Health-care charges generated by patients with

diabetes. Endocrine Practice (1998) 4:237-239.

107. Garber A, Bell DSH, Reasner C. Successful Strategies for the control of type II

Diabetes. Baylor College of Medicine and Postgraduate Institute for Medicine. A

Clinical Monograph. Editor, William E. James. 1998.

108. Bell DSH. Prudent utilization of the presently available treatment modalities for type

2 diabetes. The Endocrinologist (1998) 8:332-341.

109. Bell DSH, Ovalle F. Metformin lowers lipoprotein (a) levels. Diabetes Care (1998)

21:2028.

110. Bell DSH, Ovalle F. Troglitazone interferes with gemfibrozil’s lipid-lowering action.

Diabetes Care (1998) 21:2028-2029.

111. Bell DSH, Mayo MS. Weight loss in patients treated with a metformin-sulfonylurea

combination in comparison with twice daily mixed insulin. Endocrine Practice (1998)

4:360-364.

112. Bell DSH, Ovalle F. Using combination therapy for type 2 diabetes. IM Internal

Medicine (1999) 20:20-27.

113. Bell DSH. Use of B-Adreneregic blocking agents with diabetes – friend and foe.

Endocrine Practice (1999) 5:5l-53.

13

David S.H. Bell

114. Bell DSH, Alele J. Dealing with diabetic nephropathy. Postgraduate Medicine (1999)

105:83-94.

115. Bell DSH, Ovalle F. Gastroparesis cured by gastrectomy. Diabetes Care (1999)

22(6)1000-1001.

116. Bell DSH, Ovalle F. C-peptide utilization in clinical practice: Effect on treatment

and outcome of diabetes in a series of cases. Endcrine Practice (1999) 5(3):114-118.

117. Bell DSH, Ovalle F. Stroke management in the diabetic patient. The Journal of

Critical Illness (1999) 14:309-318.

118. Ovalle F, Bell DSH. Troglitazone’s effect on lipoprotein(a). Diabetes Care (1999)

22:859-860.

119. Bell DSH, Ovalle F. Is gastroparesis in diabetes cured by gastrectomy? Response to

Schnedl et al. Diabetes Care (1999) 22:1921.

120. Bell DSH, Ovalle F. Advances in therapy for type 2 diabetes. Patient Care (1999)

33:189-200.

121. Ovalle F, Bell DSH. Hormone replacement therapy and serum uric acid. Lancet

(1999) 354:1643-44.

122. Bell DSH, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction. Diabetes

Care (2000) 23:128-129.

123. Feld S, Hellman R, Dickey RA, Jellinger PS, Janick JJ, Rodbard HW, Cobin RH, Bell

DSH, Ganda O, Davidson ET, Siebel JA. AACE Diabetes Guidelines. Endocrine

Practice (2000) 6:42-84.

124. Bell DSH. Should anti-glutamic acid decarboxylase antibody levels be determined in

new-onset diabetes? Endocrine Practice (2000) 6(2)214-216.

125. Bell DSH. Dunluce Castle, County Antrim, Northern Ireland. The New England

Journal of Medicine (2000) 342(5)324.

126. Bell DSH. Inflammation, Insulin Resistance, Infection, Diabetes and Atherosclerosis.

Endocrine Practice (2000)6:271-275.

14

David S.H. Bell

127. Bell DSH, Ovalle F. Diabetes as a Risk Factor for Ischemic Heart Disease. Clinical

Reviews – Prevention of Coronary Heart Disease: Identification and Treatment of

Risk Factors. Robert A. Kreisberg, M.D., Editor. (Spring 2000) 88-92.

128. Bell DSH, Ovalle F. Management of Type 2 Diabetes in Clinical Reviews –

Prevention of Coronary Heart Diusease: Identification and Treatment of Risk

Factors. Robert A. Kreisberg, M.D., Editor (Spring 2000) 92-96.

129. Bell DSH, Ward J. Peripheral and Cranial Neuropathy in Diabetes. In Clinical

Diabetes Mellitus – Third Edition – John K. Davidson, M.D., Ph.Ded. Thieme, N.Y.,

N.Y. (2000) 621-635.

130. Bell DSH, Ovalle F. How Long Can Insulin Be avoided in the Patient with Type 2

Diabetes Mellitus by Use of a Combination of Metformin and a Sulfonylurea?

Endocrine Practice (2000) 6:293-295.

131. Bell DSH, Fowler MB. Comprehensive Adrenergic Blockade in Patients with

Hypertension and Diabetes. Cardiology Review (2000) 17:7(suppl)11-17.

132. Bell DSH (ed.) Diabetes Insights. Bioscience Reports (2000)1-8 Bioscience

Communications NY, NY.

133. Bell DSH. Cardiovascular Disease in South Asians. Lancet (2000) 356:1109.

134. Bell DSH. Hypertension and Antihypertensive Therapy as Risk Factors for Type 2

Diabetes Mellitus. (Letter)

135. Bell DSH, Ovalle F. Improved Glycemic Control with Use of Continuous

Subcutaneous Insulin Infusion Compared with Multiple Insulin Injection Therapy.

Endocrine Practice (2000) 6:357-360.

136. Bell DSH, Ovalle F, Shadmany S. Postprandial rather than preprandial glucose levels

should be used for adjustment of rapid-acting insulins. Endocrine Practice (2000)

6:477-478.

137. Bell DSH. Pathophysiology of type 2 diabetes and its relationship to new therapeutic

approaches. Supplement to The Diabetes Educator Journal (2000)6:477-478.

138. Bell DSH. Should angiotensin-converting enzyme inhibitors be added to the water

supply of patients with diabetes? Endocrine Practice (2001)7(1)59-63.

139. Bell DSH. Ethics in Diabetic Clinical Trials. Diabetes Care (2001)24(3):606.

15

David S.H. Bell

140. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of

thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: Review of

the evidence in animals and humans. Endocrine Practice (2001)7(2):135-137.

141. Bell DSH, Ovalle F. Use of soy protein supplement and resultant need for increased

dose of levothyroxine. Endocrine Practice (2001)7(2):135-137.

142. Bell DSH, Ovalle F, Shadmany S. Cerebellar ataxia associated with high levels of

anti-glutamic acid decarbosylase antibodies. The Endocrinologist (2001)11(3)233-235.

143. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone.

Endocrine Practice (2001) 7:326.

144. Bell DSH. Importance of postprandial glucose control. Southern Medical Journal

(2001) 94(8)804-809.

145. Go RCP, Desmond R, Roseman JM, Bell DSH, Vanichanan C, Acton RT. Prevalence

and risk factors of microalbuminuria in a cohort of African-American women with

gestational diabetes. Diabetes Care (2001)24:1764-1768.

146. Bell DSH. Drugs for cardiovascular risk reduction in the diabetic patient. Current

Diabetes Reports (2001)1:133-139.

147. Acton RT, Barton JC, Bell DSH, Go RCP, Roseman JM. HFE mutations in African-

American women with non-insulin-dependent diabetes mellitus. Ethnicity and

Disease (2001)11:578-584.

148. Bell DSH. Combination therapy for type 2 diabetes. American Family Physician

(2001)64(11)1812-1814.

149. Bell DSH. Current status of diabetes treatment. Southern Medical Journal

(2002)95(1)24-29.

150. Bell DSH. Chronic complications of diabetes. Southern Medical Journal

(2002)95(1)30-34.

151. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of

pancreatic beta cell function in patients with type 2 diabetes mellitus. Diabetes,

Obesity and Metabolism (2002)4:56-59.

152. Bell DSH. Treatment of heart failure in patients with diabetes: clinical update.

Ethnicity and Disease (2002)12(suppl 1) S1 12-18.

16

David S.H. Bell

153. Feld S, Hellman R, Dickey RA, Jellinger PS, Janick JJ, Robbard HW, Cobin RH, Bell

DSH, Gand O, Davidson ET, Siebel JA. American Association of Clinical

Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the

AACE System of Intensive Diabetes Self-Management – 2002 Update. Endocrine

Practice (2002)8(suppl1)41-82.

154. Bode B, Weinstein R, Bell DSH, McGill J, Nadeau D, Raskin P, Davidson J, Henry R,

Huang WC, Reinhardt R. Comparison of insulin aspart with buffered regular insulin

and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care

(2002)25(3)439-444.

155. Ovalle F, Bell DSH. Effect of thiazolidinediones on high-density lipoprotein

subfractions. Endocrine Practice (2002) 8(2)102-104.

156. Bell DSH. Understanding the role of insulin resistance for the treatment of diabetes

and the reduction of cardiovascular risk. Journal of Gender Specific Medicine

(2002)5:2(suppl 1)1-14.

157. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes

mellitus. Endocrine Practice (2002)8:271-275.

158. Albright ES, Ovalle F, Bell DSH. Artifactually low hemoglobin A1c caused by use of

dapsone. Endocrine Practice (2002)8(5):370-372.

159. Bell DSH, Leahy JL, Piziak VK. Achieving glycemic control with insulin in type 2

diabetes. Patient Care (2002)36(12)60-83.

160. Bell DSH. Is diabetes a cardiovascular disease? Cardiology Review (2002)19(12)15-

16.

161. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical

practice. Endocrine Practice (2002)8(6)406-410.

162. Bell DSH, Albright ES, Ovalle F. High-dose mineralocorticoid requirements in an

adrenally insufficient pregnant patient: A case report. The Endocrinologist

(2002)12:391-394.

163. Gavin JRIII, Bell DSH, Braunstein S, Henry R, Wyne K. Cardiovascular effects of

insulin resistance: Beyond glycemic control. Dialogues in Diabetes (2003)3:1-15.

164. Bell DSH, Cross LB, Masood A, McGriff-Lee N. New Product Bulletin on Avandamet

(rosiglitazone maleate and metformin Hcl) American Pharmaceutical Association

(2002) 1-12.

17

David S.H. Bell

165. Albright ES, Bell DSH. The liver, liver disease, and diabetes mellitus. The

Endocrinologist (2003)13:58-72.

166. Bell DSH. Why I initiate therapy with two insulin sensitizers in patients with type 2

diabetes. Endocrine Practice (2003)9:98-100.

167. Bell DSH. Beta-blockers in the diabetic patient. Practical Diabetology (2003) 22:20-

23.

168. Nesto RW, Bell DSH, Dandona P, Goldstein BJ, Wyne KL. Type 2 diabetes and

cardiovascular disease: Reducing the risks. Dialogues in Diabetes (2003) 3(4)1-15.

169. Bell DSH. Overview of 2002 AACE diabetes guidelines in Achieving Glycemic

Control in Diabetes Mellitus. Ingenix Fairfield NJ 1-19.

170. Bell DSH. Use of beta blockers in the patient with diabetes. The Endocrinologist

(2003)13(2):116-123.

171. Bell DSH. Beneficial effects resulting from thiazolidinediones for treatment of type 2

diabetes mellitus in A Special Report Reappraisal of Type 2 Diabetes Mellitus

Management in Primary Care New Observations. A Postgraduate Medicine Special

Report May 2003. Pages 35-52.

172. Wyne KL, Drexler AJ, Miller JL, Bell DSH, Braunstein S, Nuckolls JG. Constructing

an algorithm for managing type 2 diabetes in a Special Report Reappraisal of Type 2

Diabetes Mellitus Management in Primary Care: New Obserations. A Postgraduate

Medicine Special Report. May 2003 Pages 63-72.

173. Nesto RW, Bell DSH, Dandona P, Goldstein BJ, Wyne KL. Type 2 diabetes and

cardiovascular disease: reducing the risks. Dialogues in Diabetes (2003)3(5)1-14.

174. Bell DSH. Heart Failure. The frequent, forgotten, and often fatal complication of

diabetes. Diabetes Care (2003) 26:2433-241.

175. Bell DSH. Maximally Utilizing the Available Agents for the Treatment of Type 2

Diabetes. Clinical Medicine & Research (2003) 1(3)173-174.

176. Bell DSH. Unilateral edema due to a thiazolidinedione. Diabetes Care

(2003)26(9)2700.

177. Bell DSH. Diabetic Cardiomyopathy. Diabetes Care (2003)26:2949-2951.

178. Bell DSH. Functional class in patients with heart failure is associated with the

development of diabetes. Am J Med (2003)115(5)412.

18

David S.H. Bell

179. Bell DSH, Rushakoff RJ. How to use combination drug therapy for type 2 diabetes.

Patient Care (2003)37(9):33-44.

180. Rubin RH, Bell DSH, Childs L, Felton AE, Garber A, Gavin J III, Kudhiro JK, Mora

P, Penna P, Peyrot M, Raken R, Rodgers D. Type 2 diabetes: facing frustrations

reversing resistance. Socratic Dialogues - a supplement to Internal Medicine News

(2003)1-4.

181. Korytkowski M, Bell DSH, Jacobsen C, Suwannasari R. For the Flex Pen Study

Team. A multicenter, randomized, open-label, comparative, two-period crossover

trial of preferences, efficacy and safety profiles of a prefilled disposable pen and

conventional vial/syringe for insulin injection in patients with type 1 or type 2

diabetes mellitus. Clinical Therapeutics (2003)25(11)1-13.

182. Rubin RH, Bell DSH, Childs L, Felton AE, Garber A, Gavin J III, Kudhiro JK, Mora

P, Penna P, Peyrot M, Rakel R, Rodgers D. Type 2 diabetes: facing frustrations

reversing resistance. Socratic Dialogues a supplement to Family Practice News (2003)

1-4.

183. Bell DSH. The importance of glucose control in the treatment of type 2 diabetes:

focus on risk factor reduction. In Beneficial Effects of Glycemic Control on

Macrovascular Complications of Type 2 Diabetes ed Bell DSH. Scientific

Therapeutics Springfield, NJ (2003) Pages 1-7.

184. Bell DSH, Blonde LA, Drexler AJ, Goldstein AJ, Goldstein BJ, Wyne KL, Meredith

M. Diabetes and Cardiovascular Disease: Clinical Studies to Clinical Applications in

Dialogues in Diabetes (2003) 3(4)1-15.

185. Bell DSH. Dyslipidemia in type 2 diabetes and the effects of thiazolidinediones. The

Endocrinologist (2003) 13:496-504.

186. Albright ES, Bell DSH. Diabetic amyotrophy associated with hepatic virus C

infection. The Endocrinologist (2003)13:445-448.

187. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, LeWinter M,

Porte D, Semenkovich CF, Smith S, Young CH, Kahn R. Thiazolidinedione use, fluid

retention, and congestive heart failure? A consensus statement from the American

Heart Association and American Diabetes Association. Circulation (2003) 108:2941-

2948.

188. Bell DSH. B-Cell rejuvenation with thiazolidinediones. The American Journal of

Medicine (Proceedings of a Symposium) December 8, 2003 115(8A)20S-23S.

189. Bell DSH. Therapy for Type 2 Diabetes (In response – Lett to the Editor) Endocrine

Practice (2003)9(6):566-567.

19

David S.H. Bell

190. Nesto RW, Bell DSH,Bonow RO, Fonseca V, Grundy SM, Horton ES, LeWinter M,

Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid

retention and congestive heart failure: a consensus statement from the American

Heart Association and American Diabetes Association. Diabetes Care

(2004)(1)27:256-263.

191. Bell DSH. Secretagogues and cardiac risk. The Endocrinologist (2004) 14:33-37.

192. Bell DSH, Hardy RW, Desmond R. C-reactive protein and glycemic control in adults

with diabetes. Diabetes Care (2004)27:637-638.

193. Albright ES, Desmond R, Bell DSH. Efficacy of conversion from bedtime NPH

insulin injection to once-or twice-daily injections of insulin Glargine in Type 1

diabetic patients using basal/bolus therapy. Diabetes Care (2004)27:632-633.

194. Bell DSH. Type 2 diabetes mellitus: What is the optimal treatment regimen? AJM

(2004)116(Supplement 5A)23S-29S.

195. Bell DSH. A comparison of agents used to manage type 2 diabetes mellitus. Need for

reappraisal of traditional approaches. Treatments in Endocrinology (2004)3(2)67-76.

196. Bell DSH. Thiazolidinedione-associated congestive heart failure and pulmonary

edema. Mayo Clin Proc (2004)79:572.

197. Bell DSH. Heart failure: A serious and common comorbidity of diabetes. Clinical

Diabetes (2004)22(2)61-65.

198. Bell DSH. Advantages of a third generation B-blocker in patients with diabetes

mellitus. American Journal of Cardiology (2004)93(suppl)49B-52B.

199. Bell DSH, Ovalle F. Outcomes of initiation of therapy with once daily combination of

a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. Diabetes

Obes Metab (2004)6(5)363-366.

200. Bell DSH, Ovalle F. The role of C-peptide levels in screening for latent autoimmune

diabetes in adults. Am J Ther (2004)11(4)308-311.

201. Bell DSH. Management of type 2 diabetes with thiazolidinediones. Link between B-

cell preservation and durability of response. The Endocrinologist (2004)14(5)293-299.

202. Bell DSH. Insulin as initial therapy for type 2 diabetes is not in the patient’s best

interest. Endocrine Practice (2004)10(3)208-212.

20

David S.H. Bell

203. Wyne KL, Bell DS, Gambert SR. An algorithm for managing type 2 diabetes: A

focus on the disease process, not just the sugar. A supplement to Annals of Long-

Term Care (August, 2004)1-23.

204. Bell DSH. Single-composition extended-release metformin hydrochloride. (Guest

Commentary) Treatments in Endocrinology (2004)3(5)333.

205. Wyne KL, Bell DSH, Gambert SR. An algorithm for managing type 2 diabetes: A

focus on the disease process, not just the sugar. A Supplement to Clinical Geriatrics

(August, 2004)1-21.

206. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic B-Cell

function of subjects with type 2 diabetes. Diabetes Care (2004) 27(11)2585-2589.

207. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime

insulin glargine with bedtime neutral protamine hagedorn insulin in patients with

type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a

multicenter, randomized, parallel group study. Am J Med Sci (2004) 328(5)274-280

208. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P,

Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators.

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus

and hypertension: a randomized controlled trial. JAMA (2004) 292(18):2227-2236.

209. Bell DSH. Practical considerations and guidelines for dosing sulfonylureas as

monotherapy or combined therapy. Clinical Therapeutics (2004)26(11):1714-1727.

210. Bell DSH. Treatment of type 2 diabetes with a combination of two insulin sensitizers

– increased efficacy and fewer side-effects. Business Briefing: US Cardiology

(2004)8:29-33.

211. Bell DSH. Advances in diabetes for the millennium: the heart and diabetes.

MedGenMed. (2004)6(2):7.

212. O’Keefe JH, Bell DSH, Wyne KL, Haffner SM. Diabetes Essentials (2004) Physicians

Press, Royal Oak, Michigan.

213. The DREAM Trial Investigators. Rationale, design and recruitment characteristics

of a large, simple, international trial of diabetes prevention: the DREAM trial.

Diabetologia (2004)47:1519-1527.

21

David S.H. Bell

214. Bakris GL, Bell DSH, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright,

JT, Jr. Iyengar M, Holeslaw T, Anderson KM. The rationale and design of the

glycemic effects in diabetes mellitus Carvedilol-Metoprolol comparison in

hypertensives (GEMINI) trial. Journal of Diabetes and Its Complications (2005)

19:74-79.

215. Kirchheimer S, Bell DSH. Know your type 2 meds. Diabetes Focus (2005) 1(1) 24-26.

216. Bell, D. Latent autoimmune diabetes in adults (LADA). Clinical Laboratory

International (2005) 29(2)12-14.

217. Prelipcean MS, O’Neil PJ, Bell DSH. Hyperinsulinemic Hypoglycemia, Precipitated

by Weight Loss. Southern Medical Journal (2005) 98(7)726-728.

218. Abuissa H, Bell DSH, O’Keefe JH Jr. Strategies to prevent type 2 diabetes. Current

Medical Research and Opinions. (2005) 21(7)1107-1114.

219. Bell DSH. Optimizing treatment of diabetes and cardiovascular disease with

combined α,β-blockade. Current Medical Research and Opinions (2005)21(8)1191-

1200.

220. Bell DSH. Latent autoimmune diabetes in adults (LADA). GAD in Metabolic and

Neurologic Disease (2005) Vol II, DMCCAD, Stockholm, Sweden Pgs. 7-10.

221. Vaughan TB, Bell DSH. Statin neuropathy masquerading as diabetic autoimmune

polyneuropathy. Diabetes Care (2005) 2082.

222. Drexler, AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell DSH, Brunzell J, Dandona

P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh

W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH.

Evaluating the Cardiovascular Effects of Thiazolidinediones and Their Place in the

Management of Type 2 Diabetes in relation to the Metabolic Syndrome. Metabolic

Syndrome and Related Disorders (2005)3(2)147-173.

223. Vaughan TB, Bell DSH. Stockpiling of ovarian follicles and the response to

rosiglitazone. Diabetes Care (2005) 28(9)2333-2334.

224. Bell DSH, McGill JB. Carvedilol versus metoprolol in diabetic hypertensive patients.

Cardiology Review (2005) 22(10)12-15.

225. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P,

Wright JT Jr., Waterhouse B, Lukas MA, Anderson KM, Bell DSH; for the GEMINI

Investigators. Differential effects of β-blockers on albuminuria in patients with type 2

diabetes. Hypertension (2005)46:1309-1315.

22

David S.H. Bell

226. Bell, DSH. Differences between thiazolidinediones – Do the lipid effects really

matter? Metabolic Syndrome and Related Disorders (2005)3(3):198-201.

227. Bell, DSH. The Diabetic Heart. Journal of the Asian Federation of Endocrine

Societies (2005) 23(supplement 1)S7-S8.

228. Bell, DSH. A comparison of lipid and glycemic effects of pioglitazone and

rosiglitazone in patients with type 2 diabetes and dyslipidemia: a response to

Goldberg, et al. Diabetes Care (2005)28(12)2983-2984.

229. O’Keefe JH, Bell DSH, Wyne KL, Haffner SM. Diabetes Essentials (2005) Physicians

Press, Royal Oaks, Michigan.

230. Bell DS, Bakris GL. Carvedilol, metoprolol and insulin resistance – reply. JAMA

(2005)293:1190.

231. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with

thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes

Metab (2006)8(19):110-115.

232. Bell, DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ

(2006)174(2):185-186.

233. Bell, DSH. The effectiveness of β-blockers after myocardial infarction in patients with

type 2 diabetes. Response to McDonald, et al. Diabetes Care (2006)29(2)483.

234. Bell DS, Lukas MA, Holdbrook FK, Fowler MB. The effect of carvedilol on mortality

risk in heart failure patients with diabetes: results of a meta-analysis.

Curr Med Res Opin. (2006)22(2):287-96.

235. Bell, DSH. Diabetic Hypertensive Pre-Heart Failure Patient in Heart Failure Clinics

(2006)2(1) Bell, DSH (editor) Elsevier Saunders New York, New York XIII-XVI.

236. Vaughan TB, Bell DSH. Diabetic Cardiomyopathy in Heart Failure Clinics (2006)2(1)

Bell DSH (editor) Elsevier Saunders New York, New York 71-80.

237. Bell, DSH. “Dead in bed syndrome – an hypothesis”. Diabetes Obesity and

Metabolism (2006)8(3)261-263.

238. Bell, DS. The case for combination therapy as first-line treatment for the type 2

diabetic patient. Treat Endocrinol. 2006;5(3):131-7.

239. McGill JB, Bell DSH. Anemia and the roles of erythropoietin in diabetes. J Diabetes

Complications (2006)20(4)262-272.

23

David S.H. Bell

240. Bell DSH, Wyne KL. Treatment of type 2 diabetes. Use of fixed-dose oral

combinations. Postgrad Med (2006)119(2)8-14.

241. Bell DSH, Wyne KL. Treatment of type 2 diabetes. The addition of injection therapy.

Postgrad Med(2006)119(2)15-20.

242. Bell DSH, McGill JB, Fonseca V. Impact of carvedilol on microalbuminuria is

independent of the statin effect. Diabetologia (2006)49(supplement 1)640.

243. Bell, DSH. Hypertension, diabetes, insulin resistance, and postprandial

hyperglycemia. Drug Development Research (2006)67(7)595-596.

244. The DREAM Trial Investigators. Effect of ramapril on the incidence of diabetes. N

Eng J Med (2006)355:1551-1562.

245. The DREAM (Diabetes Reduction Assessment with ramapril and rosiglitazone

Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes

in patients with impaired glucose tolerance or impaired fasting glucose: a

randomized, controlled trial. Lancet (2006)368:1096-1105.

246. Bell DSH, O’Keefe JH, Bakris GL. Handbook of Diabetic Hypertension (2006)

Physicians Press, Royal Oaks, Michigan.

247. Bell, DS. Comment on: From the coalface: does glargine insulin improve

hypoglycemic episodes, glycemic control or affect body mass in type 1 diabetic

subjects who are attending a “routine” diabetic clinic? Diabetologia (2007)49:2793-

2794.

248. McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE,

Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. Beta-

Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes

Obes Metab. 2007 May;9(3):408-17.

249. Bell, DSH. Treatment of infertility in the polycystic ovary syndrome. N Eng J Med

(2007)356:1999-2000.

250. O’Keefe JH, Bell DSH, Wyne KL, Haffner SM. Diabetes Essentials – third edition

(2007) Physicians Press Royal Oak, Michigan.

251. Bell DSH. Allbright E. The multifaceted associations of hepatobilary disease and

diabetes. Endocr. Pract. (2007)13:300-312.

252. Fonseca V, Bakris GL, Bell DSH, McGill JB, Raskin P, Messerli FH, Philips RA,

Katholi RE, Wright JT, Waterhouse B, Lukas MA, Anderson KM. Differential effect

of β-blocker therapy or insulin resistance as a function of insulin sensitizer use:

results from GEMINI. Diabetic Medicine (2007)24(7)759-63.

24

David S.H. Bell

253. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P,

Wright JT, Bangalore S, Holdbrook FK, Lucas MA, Anderson KM, Bakris GL;

GEMINI Investigators. Body weight changes with beta-blocker use: results from

GEMINI. Am J Med (2007)120(7):610-5.

254. Bell, DSH. Insulin therapy in diabetes mellitus: how can the currently available

injectable insulins be most prudently and efficaciously utilized? Drugs

(2007)67(13)1813-1827.

255. O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial

dysmetabolism) is a cardiovascular risk factor. Am J Cardiol (2007)100(5)899-904.

256. Bell DS, O’Keefe JH. White cell count, mortality, and metabolic syndrome in the

Baltimore longitudinal study of aging. J Am Coll Cardiol (2007)50(18):1810.

257. Baalbaki HA, Bell DS. Insulin resistance and thrombogenesis: recent insights and

therapeutic implications. Endocr Pract (2007)13(6)679-86.

258. Wright JT Jr, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH,

Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M. Lowering Blood

Pressure With beta-Blockers in Combination With Other Renin-Angiotensin System

Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the

GEMINI Trial. J Clin Hypertens (Greenwich). (2007)9(11):842-849.

259. Bell, DS. Triple oral therapy for type 2 diabetes. Diabetes Res Clin Pract.

(2007)78(3):313-315.

260. Bell, DSH. Heart failure in the diabetic patient. Cardiol Clin (2007)25:523-538.

261. Bell, DSH. Diabetes Update. Audio – Digest Internal Medicine (2007)54:23.

262. Bell DS, McGill JB, Fonseca VA. The decrease in microalbuminuria with carvedilol

therapy is not enhanced by concurrent use of a statin. Endocr Pract. (2007)13(7):808-

9.

263. Bell, DSH. Postprandial dysmetabolism as a cardiac risk factor. Endocrine Today

(2008)6(1)15.

264. Bell DSH, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link

between diabetes and cardiovascular events? Endocr Pract(2008)14(1):112-124.

265. Bell, DSH. What is the cause of “dead in bed” syndrome? Endocrine Today

(2008)6(7)3.

25

David S.H. Bell

266. The DREAM Trial Investigators. Effects of ramapril and rosiglitazone on

cardiovascular and renal outcomes in people with impaired glucose tolerance or

impaired fasting glucose. Diabetes Care (2008)31:1007-1014.

267. Bell DSH. The role of vitamin D for obese patients in reversing the type 2 diabetes

pandemic. Endocrine Today (2008)6(15)4.

268. Bell DS, O’Keefe JH. Use of alternative thresholds defining insulin resistance to

predict type 2 diabetes mellitus and cardiovascular disease. Circulation

(2008)118(11)e156.

269. Bell, DS. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocrine

Practice (2008)14(7):924-932.

270. Bell, DSH. Peyronie disease in association with carvedilol: a case report. Southern

Medical Journal (2008)101(11)1157-1158.

271. Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P,

Wright Jr JT, Iyengar M, Anderson KM, Lukas MA, Bakris GL; for the GEMINI

Investigators. Demographic Analyses of the Effects of Carvedilol vs Metoprolol on

Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and

Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol

Comparison in Hypertensives (GEMINI) Study. J Cardiometab Syndr.

(2008)3(4):211-217.

272. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an

important, common, and easily treatable cardiovascular risk factor? J Am Coll

Cardiol. (2008)52(24):1949-1956.

273. Bell, DSH. Hypertension and diabetes – a toxic combination. Endocrine Practice

(2008)14(8):1031-1039.

274. Bell, DSH. Diabetes and cardiovascular risk. US Endocrinology (2008)4(1):79-82.

275. Bell, DSH. Management of new-onset diabetes mellitus after transplantation.

Postgrad Med (2009)121(1)161-163.

276. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum

lipid concentration in diabetic hypertensive patients. Diabetes Obesity and

Metabolism (2009)11(3)234-238.

277. Bell, DSH. Treatment of diabetic hypertension. Diabetes Obesity and Metabolism

(2009)11(5)433-444.

278. O’Keefe JH, Bell DS, Wyne KL. Diabetes Essentials Fourth Edition (2009) Jones and

Bartlett. Sudbury, MA USA.

26

David S.H. Bell

279. Bell, DSH. Importance of postprandial glucose levels in type 2 diabetes. Southern

Medical Journal (2009)102(5):553.

280. Bell, DSH. The risk of developing coronary artery disease or congestive heart failure

and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone,

metformin or sulfonylureas: a retrospective analysis. Acta Diabetologia

(2009)102(4)413-415.

281. Bell, DSH. Successful utilization of aliskiren, a direct renin inhibitor in Bartter

syndrome. SMJ (2009)102(4)413-415.

282. Bell DS, O’Keefe JH. Metabolic syndrome and postoperative atrial fibrillation

(POAF). Eur Heart J (2009)30(10)1167-1168.

283. O’Keefe JH, Carter MD, Lavia CJ, Bell DSH. The gravity of JUPITER. Justification

for the use of statins in primary prevention: an intervention trial evaluating

rosuvastatin. Postgraduate Medicine (2009)121(3)113-118.

284. Bell DSH, Bruton S, Morales J, White RD. The role of insulin therapy for type 2

diabetes: a primary care roundtable. Medscape CME 7/21/2009.

285. Bell, DSH. The association of obesity, metabolic syndrome, diabetes and

cardiovascular disease with non-alcoholic fatty liver disease. Southern Medical

Journal (2009)102(10)991-992.

286. Bell, DSH. Innovative utilization of existing and soon-to-be available therapies for

type 2 diabetes. Joslin Publications. Boston, USA (2009)2:1-21.

287. Bell DSH, O’Keefe JH. Rediscovering bile acid sequestrants. Diabetes, Obesity and

Metabolism (2009)11:1114-1125.

288. Bell, DSH. Cardiac considerations in the treatment of the metabolic syndrome.

Heart and Metabolism (2009)45:20-25.

289. Bell, DSH. Metformin-induced vitamin B12 deficiency presenting as a peripheral

neuropathy. Southern Medical Journal(2010)103(3)265-267.

290. Bell DSH, O'Neill PJ. Hyperandrogenemia in a postmenopausal female that is

suppressed with metformin can avoid unnecessary surgery. The Endocrinologist

(2010)20:83-85.

291. Bell, DSH. Hyperglycemia and ketosis induced by gamma hydroxy-butarate (GHB).

Diabetologia(2010)53(7)1539-1540.

292. Bell, DSH. Resolution of statin-induced myalgias by correcting vitamin D deficiency.

Southern Medical Journal(2010)103(7)690-692.

27

David S.H. Bell

293. Bell, DSH. Nocturnal hypoglycaemia presenting as somnambulism.

Diabetologia(2010)53:2066-2067.

294. Bell DSH, O'Keefe JH. Metabolic Syndrome Essentials(2011)Jones and Bartlett,

Sudbury, MA, USA.

295. Bell, DS. Goals for HbA1c Need To Be Individualized Based on Clinical Judgment,

Instead of Third Party Recommendations. Southern Medical

Journal(2010)103(9)854-5.

296. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS. Strategies for optimizing glycemic

control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo

Clinic Proceedings(2011)86(2)128-138.

297. Bell DS, Al Badarin F, O'Keefe JH Jr. Therapies for diabetic dyslipidaemia.

Diabetes Obes Metab(2011)13(4):313-25.

298. Bell, DS. Protean manifestations of vitamin D deficiency, part 1: the epidemic of

deficiency. Southern Medical Journal(2011)104(5)331-334.

299. Bell, DS. Protean manifestations of vitamin D deficiency, part 2: deficiency and its

association with autoimmune disease, cancer, infection, asthma, dermopathies, insulin

resistance and type 2 diabetes. Southern Medical Journal(2011)104(5)335-339.

300. Bell, DS. Protean manifestations of vitamin D deficiency, part 3: association with

cardiovascular disease and disorders of the central and peripheral nervous systems.

Southern Medical Journal(2011)104(5)340-344.

301. Bell, DSH. Response to "More Adverse Neurological Consequences of Metformin-

Induced Vitamin B12 Deficency". Southern Medical Journal(2011)104(7)542.

302. Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose

diabetes polypill versus insulin plus metformin efficiacy demonstration study in the

treatment of advanced type 2 diabetes (TrIED study -II). Diabetes Obes

Metab(2011)13(9)800-805.

303. Bell DS, O'Keefe JH. Lowering the triglyceride-high density lipoprotein cholesterol

ratio and its association with the beneficial impact of pioglitazone on coronary

atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.

J Am Coll Cardiol(2011)58(7)778.

304. Bell, DSH. Why does quick-release bromocriptine decrease cardiac events? Diabetes

Obes Metab(2011)13(10)880-884.

305. Morales J, Bell DSH, Funnell M, Branton S. The essential guide to the management

of type 2 diabetes. Primary Care Publications Inc. Charlotte, NC (2011)1-54.

28

David S.H. Bell

306. Bell, DSH. Vitamin D deficiency and diabetes. Practical Diabetology(2011)30(4)6-21.

307. Bell DS. Beware the low urine pH - the major cause of the increased prevalence of

nephrolithiasis in the patient with type 2 diabetes. Diabetes Obesity

Metabolism(2012)14(4)299-303.

308. Bell, DSH. Accuracy of self-mixed small quantities of insulin. Endocrine Practice

(2012)18(4)616-617.

309. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in

type 2 diabetes mellitus. Am J Cardiol(2012)110(6)826-833.

310. Bell, DSH. Focusing on cardiovascular disease in type 2 diabetes mellitus: an

introduction to bromocriptine QR. Postgraduate Med(2012)124(5)121-135.

311. David S. H. Bell. Reversal of the symptoms of diabetic neuropathy through

correction of vitamin D deficiency in a type 1 diabetic patient. Case Reports in

Endocrinology, vol. 2012, Article ID 165056, 3 pages, 2012.

312. Bell, DS. Combine and conquer. Diabetes, Obesity and Metabolism(2013)15(4)291-

300.

313. Bell, DS. Apparent Recurrence of Hyperparathyroidism following Quadruple

Parathyroidectomy. Case Rep Endocrinol(2013)2013:912701. Epub 2013 Apr 23.

314. Bell, DS. On the efficacy of CSII for type 2 diabetes. Endocr Pract(2013)19(5)892-

893.

315. Bell DSH, Patil HR, O'Keefe JH. Divergent effects of various diabetes drugs on

cardiovascular prognosis. Reviews in Cardiovascular Medicine(2013)14(2-4)e107-

e122.

316. Bell, DSH. Third party payers fail to recognize the endocrinologist as a specialist.

Endocrine Today(2014)12(2):5.

317. Bell, DSH. The potent synergistic effects of the combination of liraglutide and

canagliflozin on glycemic control and weight loss. Am J Case Rep (2014)15:152-154.

318. Bell, DSH. Obesity epidemic: more than just overeating. Endocrine

Today(2013)12(5)2.

319. O'Keefe JH, DiNicolantonio JJ, Lavie CJ, Bell DSH. The influence of statins on

glucose tolerance and incipient diabetes. US Endocrinology(2014)68-74.

29

David S.H. Bell

320. Bell DS, DiNicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically

relevant? A comprehensive review of the literature. Diabetes Obes

Metab(2014)16(8)689-694.

321. Albadarin F, Bell DS, O'Keefe JH. Reply. Am J Cardiol(2015)115(6):852-3.

322. Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1

diabetic patient. Case Rep Endocrinol(2015)676191.

323. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-

Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β-Blockers in hypertension, diabetes, heart

failure and acute myocardial infarction: a review of the literature. Open

Heart(2015)2(1):e000230.

324. Bell DS. Prevention of Recurrent Nephrolithiasis in Adults. Ann Intern

Med(2015)162(7):528.

325. Bell DSH. Nondiabetic Neuropathy in a Patient with Type 2 Diabetes. In Diabetes

Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American

Diabetes Association(2015)361-363.

326. Bell DSH. Severe Distal Symmetrical and Autonomic Neuropathy in a Patient with a

Short Duration of Type 1 Diabetes. In Diabetes Case Studies. Draznin B, Low Wang

CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)364-366.

327. Bell DSH. Resolution of Infertility with Diabetes Therapy. In Diabetes Case Studies.

Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes

Association(2015)372-374.

328. Bell DSH. Reversal of Insulin-Requiring Type 2 Diabetes and Development of

Hypoglycemia in a Morbidly Obese Patient. In Diabetes Case Studies. Draznin B,

Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes

Association(2015)329-331.

329. Bell DSH. High GAD Antibody Levels and Cerebellar Atrophy in a Patient with Type

1 Diabetes. In Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds.

Alexandria, VA, American Diabetes Association(2015)369-371.

330. Bell DSH. Somnambulism (Sleepwalking) Caused by Nocturnal Hypoglycemia. In

Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA,

American Diabetes Association(2015)301-303.

331. Bell DSH. Diabetic Amyotrophy and Neuropathic Cachexia. In Diabetes Case Studies.

Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes

Association(2015)367-368.

30

David S.H. Bell

332. Bell DSH. An Unexplained Decline in HbA1c in Spite of Persistent Hyperglycemia. In

Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA,

American Diabetes Association(2015)90-91.

333. Bell DSH. Almost All Nonobese Young People with an Acute Onset of Diabetes Have

Type 1 Diabetes. In Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds.

Alexandria, VA, American Diabetes Association(2015)70-72.

334. Bell DSH. Type 1 Diabetes Can Present at Any Age. In Diabetes Case Studies.

Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes

Association(2015)61-63.

335. Bell, DSH. Diabetes therapy and cardiac risk. Cleve Clin J Med(2015)82(3)140.

336. Bell, DS. Type 2 Diabetes. Ann Intern Med(2015) 163(4) 332.

337. Bell DS. Changes seen in gut bacteria content and distribution with obesity:

causation or association? Postgrad Med(2015)127(8)863-8.

338. Bell DS. Riceabetes: is the association of type 2 diabetes with rice intake due to a high

carbohydrate intake or due to exposure to excess inorganic arsenic? Postgrad

Med(2015)127(8)781-2.

339. Bell, DS. Aspirin in the prevention of cardiovascular events in patients with diabetes.

Postgraduate Med(2016)128(2)180-90.

340. Bell, DS. The facts about diabetes: eye disease. Empower(2016)1:16-18.

341. Bell, DS. Metformin: A lifesaver for those with and without diabetes. Practical

Diabetology(2016)35(1)16-17.

342. Bell, DS. Cutting edge versus cutting cost. Practial Diabetology(2016)Sept/Oct:12-16.

343. Bell, DS. Statin-induced diabetes: risks, benefits and clinical results. Practial

Diabetology(2016)Nov/Dec:16-19.

344. Bell, DS. Human medicines inappropriately used in animals come at a much lower

cost. Southern Medical Journal(2017)110(1)78.

345. Bell, DS. Mechanisms by which metformin improves mortality and hospital

readmission in diabetic patients with heart failure. Endocrine

Practice(2017)23(3)379.

346. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber

AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K,

Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical

31

Endocrinologists and American College of Endocrinology guidelines for management

of dyslipidemia and prevention of caerdiovascular disease. Endocr

Pract(2017)23(Suppl 2):1-87.

347. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber

AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K,

Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical

Endocrinologists and American College of Endocrinology guidelines for management

of dyslipidemia and prevention of cardiovascular disease- Executive

summary<sub>Complete Appendix to Guidelines available at

http://journals.aace.com</sub>. Endocr Pract(2017)23(4)479-497.

348. Bell, DS. Oral pharmacologic treatment of type 2 diabetes. Annals of Internal

Medicine(2017)167(1)74-75.

349. Bell DSH, Goncalves, E. The Cadillac combination for type 2 diabetes: A GLP-1

receptor agonist and a SGLT2 inhibitor. Practical Diabetology(2017)36(3)10-13.

350. Herman ME, O'Keefe JH, Bell DSH, Schwartz SS. Insulin Therapy Increases

Cardiovascular Risk: Time for a Sea of Change in Type 2 Diabetes Treatment. Prog

Cardiovasc Dis(2017)60(3)422-434.

351. Bell, DSH. Re: Diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2

inhibitors: an ongoing concern. Endocrine Practice(2018)24(1)126.

352. Goncalves E, Bell DSH. Combination treatment of SGLT2 inhibitors and GLP1

receptor agonists;symbiotic effects on metabolism and cardiorenal risk. Diabetes

Ther(2018)9(3)919-926.

353. Bell DSH. Finally, after 56 years of type 1 diabetes: a regimen that works. Postgrad

Med(2018)130(4)409-410.

354. Bell DSH, Goncalves E. Should we still be utilizing warfarin in the type 2 diabetic

patient? Diabetes Obes Metab(2018)May 22. doi: 10.1111/dom.13371. [Epub ahead of

print].

355. Bell, DSH. Correlation between serum uric acid and diabetic peripheral neuropathy

– association rather than causation. Journal of Neurological Sciences(2018)390:208

doi: 10.1016.

356. Goncalves E, Bell, DSH. HbA1c increases after unwarranted prescription change.

Diabetes Obesity and Metabolism(2018).